Sudden death and ion channel disease: Pathophysiology and implications for management

Heart

Volumn 97, Issue 17, 2011, Pages 1365-1372

  Bastiaenen, Rachel ^a   Behr, Elijah R ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANKYRIN; ANKYRIN B; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL CAV1.2; CALCIUM CHANNEL CAV1.2ALPHA1C; CALCIUM CHANNEL CAVBETA2; CALCIUM CHANNEL L TYPE; CALCIUM ION; CAVEOLIN 3; FLECAINIDE; INWARDLY RECTIFYING POTASSIUM CHANNEL; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR2.1; POTASSIUM CHANNEL KCNQ1; POTASSIUM CHANNEL KV11.1 ALPHA; POTASSIUM CHANNEL KV7.1 ALPHA; POTASSIUM ION; PROTEIN AKAP9; QUINIDINE; SODIUM CHANNEL; SODIUM CHANNEL NAV1.5; SODIUM CHANNEL NAV1.5 ALPHA; SODIUM CHANNEL NAV1.5BETA4; SODIUM CHANNEL NAVBETA; SODIUM CHANNEL NAVBETA3; SODIUM ION; SYNTROPHIN; SYNTROPHIN A1; UNCLASSIFIED DRUG;

AKAP9 GENE; ANK2 GENE; ARRHYTHMOGENESIS; ASYMPTOMATIC DISEASE; AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE INHERITANCE; BRUGADA SYNDROME; CACNA1C GENE; CACNA2D1 GENE; CACNB2 GENE; CALCIUM CURRENT; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; CAUSE OF DEATH; CAV3 GENE; CHANNEL GATING; CHANNELOPATHY; DEFIBRILLATOR; EARLY REPOLARIZATION SYNDROME; ECG ABNORMALITY; GAIN OF FUNCTION MUTATION; GENE; GENETIC SCREENING; GENOTYPE; GPD1L GENE; HEART ARRHYTHMIA; HEART LEFT VENTRICLE OUTFLOW TRACT; HEART MUSCLE CELL; HEART MUSCLE FIBER MEMBRANE POTENTIAL; HEART REPOLARIZATION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE FIBRILLATION; HUMAN; KCNE1 GENE; KCNE2 GENE; KCNE3 GENE; KCNH2 GENE; KCNJ2 GENE; KCNQ1 GENE; LONG QT SYNDROME; LOSS OF FUNCTION MUTATION; MEMBRANE DEPOLARIZATION; PATHOPHYSIOLOGY; PENETRANCE; POTASSIUM CURRENT; PRIORITY JOURNAL; QRS COMPLEX; REPOLARIZATION; REVIEW; RISK ASSESSMENT; SCN1B GENE; SCN3B GENE; SCN4B GENE; SCN5A GENE; SNTA1 GENE; SODIUM CURRENT; ST SEGMENT ELEVATION; SUDDEN ARRHYTHMIC DEATH SYNDROME; SUDDEN DEATH; SYNCOPE; T WAVE;

BRUGADA SYNDROME; CHANNELOPATHIES; DEATH, SUDDEN, CARDIAC; HUMANS; LONG QT SYNDROME; RISK ASSESSMENT; TACHYCARDIA, VENTRICULAR;

EID: 80051551296     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2011.223883     Document Type: Review

References (57)

1. Papadakis M, Sharma S, Cox S, et al. The magnitude of sudden cardiac death in the young: a death certificate-based review in England and Wales. Europace 2009;11:1353-8.
2. Behr ER, Casey A, Sheppard M, et al. Sudden arrhythmic death syndrome: a national survey of sudden unexplained cardiac death. Heart 2007;93:601-5. (Pubitemid 46707114)
3. Behr E, Wood DA, Wright M, et al. Cardiological assessment of first-degree relatives in sudden arrhythmic death syndrome. The Lancet 2003;362:1457-9. (Pubitemid 37352884)
4. Behr ER, Dalageorgou C, Christiansen M, et al. Sudden arrhythmic death syndrome: familial evaluation identifies inheritable heart disease in the majority of families. Eur Heart J 2008;29:1670-80. (Pubitemid 351957547)
5. Fabre A, Sheppard MN. Sudden adult death syndrome and other non-ischaemic causes of sudden cardiac death. Heart 2006;92:316-20.
6. Tan HL, Hofman N, van Langen IM, et al. Sudden unexplained death: heritability and diagnostic yield of cardiological and genetic examination in surviving relatives. Circulation 2005;112:207-13. (Pubitemid 40982303)
7. van der Werf C, Hofman N, Tan HL, et al. Diagnostic yield in sudden unexplained death and aborted cardiac arrest in the young: The experience of a tertiary referral center in The Netherlands. Heart Rhythm 2010;7:1383-9.
8. Arnestad M, Crotti L, Rognum TO, et al. Prevalence of long-QT syndrome gene variants in sudden infant death syndrome. Circulation 2007;115:361-7. (Pubitemid 46148510)
9. Kaab S, Schulze-Bahr E. Susceptibility genes and modifiers for cardiac arrhythmias. Cardiovasc Res 2005;67:397-413. (Pubitemid 41019548)
10. Kapplinger JD, Tester DJ, Alders M, et al. An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm 2010;7:33-46.
11. Hedley PL, Jørgensen P, Schlamowitz S, et al. The genetic basis of long QT and short QT syndromes: A mutation update. Hum Mutat 2009;30:1486-511.
12. Marban E. Cardiac channelopathies. Nature 2002;415:213-18. (Pubitemid 34059527)
13. Neher E, Sakmann B, Steinbach J. The extracellular patch clamp: a method for resolving currents through individual open channels in biological membranes. Pflugers Arch 1978;375:219-28. (Pubitemid 8383955)
14. Wolf CM, Berul CI. Molecular mechanisms of inherited arrhythmias. Curr Genomics 2008;9:160-8. (Pubitemid 351895019)
15. Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 2005;111:659-70.
16. Govindan M, Batchvarov VN, Raju H, et al. Utility of high and standard right precordial leads during ajmaline testing for the diagnosis of Brugada syndrome. Heart 2010;96:1904-8.
17. Burashnikov E, Pfeiffer R, Barajas-Martinez H, et al. Mutations in the cardiac L-type calcium channel associated with inherited J-wave syndromes and sudden cardiac death. Heart Rhythm 2010;7:1872-82.
18. Hoogendijk MG, Opthof T, Postema PG, et al. The Brugada ECG Pattern: a marker of channelopathy, structural heart disease, or neither? Toward a unifying mechanism of the Brugada syndrome. Circ Arrhythm Electrophysiol 2010;3:283-90.
19. Ohgo T, Okamura H, Noda T, et al. Acute and chronic management in patients with Brugada syndrome associated with electrical storm of ventricular fibrillation. Heart Rhythm 2007;4:695-700. (Pubitemid 46840335)
20. Viskin S, Wilde AAM, Tan HL, et al. Empiric quinidine therapy for asymptomatic Brugada syndrome: Time for a prospective registry. Heart Rhythm 2009;6:401-4.
21. Nademanee K, Veerakul G, Chandanamattha P, et al. Prevention of ventricular fibrillation episodes in Brugada syndrome by catheter ablation over the anterior right ventricular outflow tract epicardium. Circulation 2011;123:1270-9.
22. Probst V, Veltmann C, Eckardt L, et al. Long-term prognosis of patients diagnosed with Brugada syndrome: Results from the FINGER Brugada Syndrome Registry. Circulation. 2010;121:635-43.
23. Raju H, Papadakis M, Govindan M, et al. Low prevalence of markers of sudden cardiac death in victims of Brugada syndrome. J Am Coll Cardiol 2011;57:2340-5.
24. Eckardt L, Probst V, Smits JPP, et al. Long-term prognosis of individuals with right precordial ST-segment-elevation Brugada syndrome. Circulation 2005;111:257-63. (Pubitemid 40165330)
25. Kamakura S, Ohe T, Nakazawa K, et al. Long-term prognosis of probands with Brugada-pattern ST-elevation in leads V1-V3. Circ Arrhythm Electrophysiol 2009;2:495-503.
26. Paul M, Gerss J, Schulze-Bahr E, et al. Role of programmed ventricular stimulation in patients with Brugada syndrome: a meta-analysis of worldwide published data. Eur Heart J 2007;28:2126-33. (Pubitemid 47517430)
27. Morita H, Kusano KF, Miura D, et al. Fragmented QRS as a marker of conduction abnormality and a predictor of prognosis of Brugada syndrome. Circulation 2008;118:1697-704.
28. Nishii N, Ogawa M, Morita H, et al. SCN5A mutation is associated with early and frequent recurrence of ventricular fibrillation in patients with Brugada syndrome. Circ J 2010;74:2572-8.
29. Meregalli PG, Tan HL, Probst V, et al. Type of SCN5A mutation determines clinical severity and degree of conduction slowing in loss-of-function sodium channelopathies. Heart Rhythm 2009;6:341-8.
30. Antzelevitch C, Yan G-X. J wave syndromes. Heart Rhythm 2010;7:549-58.
31. Benito B, Guasch E, Rivard L, et al. Clinical and mechanistic issues in early repolarization: of normal variants and lethal arrhythmia syndromes. J Am Coll Cardiol 2010;56:1177-86.
32. Schwartz P, Moss A, Vincent G, et al. Diagnostic criteria for the long QT syndrome. An update. Circulation 1993;88:782-4. (Pubitemid 23228078)
33. Roden DM. Torsade de pointes. Clin Cardiol 1993;16:683-6. (Pubitemid 23264091)
34. Moss AJ, Shimizu W, Wilde AAM, et al. Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. Circulation 2007;115:2481-9. (Pubitemid 46763221)
35. Garratt CJ, Elliott P, Behr E, et al. Heart Rhythm UK position statement on clinical indications for implantable cardioverter defibrillators in adult patients with familial sudden cardiac death syndromes. Europace 2010;12:1156-75.
36. Schwartz PJ, Priori SG, Cerrone M, et al. Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation 2004;109:1826-33. (Pubitemid 38509115)
37. Sauer AJ, Moss AJ, McNitt S, et al. Long QT syndrome in adults. J Am Coll Cardiol 2007;49:329-37. (Pubitemid 46097383)
38. Liu JF, Jons C, Moss AJ, et al. Risk factors for recurrent syncope and subsequent fatal or near-fatal events in children and adolescents with long QT syndrome. J Am Coll Cardiol 2011;57:941-50.
39. Locati EH, Zareba W, Moss AJ, et al. Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the international LQTS registry. Circulation 1998;97:2237-44. (Pubitemid 28265385)
40. Hintsa T, Puttonen S, Toivonen L, et al. A history of stressful life events, prolonged mental stress and arrhythmic events in inherited long QT syndrome. Heart 2010;96:1281-6.
41. Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 2001;103:89-95. (Pubitemid 32050441)
42. Goldenberg I, Bradley J, Moss A, et al. Beta-blocker efficacy in high-risk patients with the congenital long-QT syndrome types 1 and 2: implications for patient management. J Cardiovasc Electrophysiol 2010;21:893-901.
43. Makita N, Behr E, Shimizu W, et al. The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome. J Clin Invest 2008;118:2219-29. (Pubitemid 351872340)
44. Goldenberg I, Horr S, Moss AJ, et al. Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervals. J Am Coll Cardiol 2011;57:51-9.
45. Zareba W, Moss AJ, Schwartz PJ, et al. Influence of the genotype on the clinical course of the long-QT syndrome. N Engl J Med 1998;339:960-5. (Pubitemid 28455098)
46. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003;348:1866-74. (Pubitemid 36532312)
47. Goldenberg I, Moss AJ, Peterson DR, et al. Risk factors for aborted cardiac arrest and sudden cardiac death in children with the congenital long-QT syndrome. Circulation 2008;117:2184-91.
48. Seth R, Moss AJ, McNitt S, et al. Long QT syndrome and pregnancy. J Am Coll Cardiol 2007;49:1092-8. (Pubitemid 46349501)
49. Tomás M, Napolitano C, De Giuli L, et al. Polymorphisms in the NOS1AP gene modulate QT interval duration and risk of arrhythmias in the long QT syndrome. J Am Coll Cardiol 2010;55:2745-52.
50. Crotti L, Lundquist AL, Insolia R, et al. KCNH2-K897T is a genetic modifier of latent congenital long-QT syndrome. Circulation 2005;112:1251-8. (Pubitemid 41266719)
51. Leenhardt A, Lucet V, Denjoy I, et al. Catecholaminergic polymorphic ventricular tachycardia in children: A 7-year follow-up of 21 patients. Circulation 1995;91:1512-19.
52. Priori SG, Napolitano C, Tiso N, et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 2001;103:196-200. (Pubitemid 32095402)
53. Cerrone M, Napolitano C, Priori SG. Catecholaminergic polymorphic ventricular tachycardia: A paradigm to understand mechanisms of arrhythmias associated to impaired Ca2+ regulation. Heart Rhythm 2009;6:1652-9.
54. Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 2002;106:69-74. (Pubitemid 34747444)
55. Wilde AAM, Bhuiyan ZA, Crotti L, et al. Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia. N Engl J Med 2008;358:2024-9. (Pubitemid 351656456)
56. Hwang HS, Hasdemir C, Laver D, et al. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia. Circ Arrhythm Electrophysiol 2011;4:128-35.
57. Sacher F, Probst V, Iesaka Y, et al. Outcome after implantation of a cardioverter-defibrillator in patients with brugada syndrome: a multicenter study. Circulation 2006;114:2317-24. (Pubitemid 44847448)